Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | PREP | P48147 | 4/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | WDR5 | P61964 | 2/20 | 0.39 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.35 |
| ▸ | STS | P08842 | 1/20 | 0.35 |
| ▸ | CETP | P11597 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.33 |
| ▸ | AR | P10275 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18100260 | 0.81 | CHRM2 (0.50) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL8241867 | 0.81 | CHRM2 (0.50) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL16806447 | 0.81 | CHRM2 (0.50) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL16358923 | 0.81 | CHRM2 (0.47) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL24663396 | 0.80 | CHRM2 (0.49) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL22957599 | 0.80 | CHRM2 (0.49) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL1574164 | 0.80 | CHRM2 (0.46) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL20682190 | 0.79 | CXCR3 (0.39) | CHRM2CHRM1CHRM3HSD11B1WDR5 | |
| SCHEMBL19216142 | 0.79 | CHRM2 (0.48) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL2446710 | 0.79 | CHRM2 (0.48) | CHRM2CHRM1CHRM3PREPHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236046-B2 | Substituted heterocyclic sulfonamide compounds useful as TRPA1 modulators | GENENTECH, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-11236046-B2 | Substituted heterocyclic sulfonamide compounds useful as TRPA1 modulators | GENENTECH, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20200048197-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | GENENTECH, INC. (US) | 2020-02-13 | — | — | US | disclosed |
| US-20200048197-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | GENENTECH, INC. (US) | 2020-02-13 | — | — | US | disclosed |
| EP-3055302-B1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | HOFFMANN LA ROCHE (CH) | 2018-12-26 | — | — | EP | disclosed |
| US-20180282272-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | GENENTECH, INC. (US) | 2018-10-04 | — | — | US | disclosed |
| US-20180118680-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | GENENTECH, INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-20180118680-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | GENENTECH, INC. (US) | 2018-05-03 | — | — | US | disclosed |
| EP-3055302-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2016-08-17 | — | — | EP | disclosed |
| US-20160221945-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | GENENTECH, INC. (US) | 2016-08-04 | — | — | US | disclosed |
| US-20160221945-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | GENENTECH, INC. (US) | 2016-08-04 | — | — | US | disclosed |
| US-20160221945-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | GENENTECH, INC. (US) | 2016-08-04 | — | — | US | disclosed |
| WO-2015052264-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-04-16 | — | — | WO | disclosed |
| WO-2015052264-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160221945-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | TRPA1, TRPV1, TRPV2 | CHRM2 2473/4885CHRM1 2859/4885CHRM3 1909/4885 |
| US-20180282272-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | TRPA1, TRPV1, TRPV2 | CHRM2 2473/4885CHRM1 2859/4885CHRM3 1909/4885 |
| US-20180118680-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | TRPA1, TRPV1, TRPV2 | CHRM2 2473/4885CHRM1 2859/4885CHRM3 1909/4885 |
| US-20200048197-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | TRPA1, TRPV1, TRPV2 | CHRM2 2473/4885CHRM1 2859/4885CHRM3 1909/4885 |
| US-11236046-B2 | Substituted heterocyclic sulfonamide compounds useful as TRPA1 modulators | TRPA1, TRPV1, TRPV2 | CHRM2 2473/4885CHRM1 2859/4885CHRM3 1909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.